Oncolytics Biotech Inc., of Calgary, Alberta, said interim Phase II data showed intravenous administration of Reolysin in combination with Gemzar (gemcitabine, Eli Lilly and Co.) in patients with advanced pancreatic cancer met the study's primary endpoint.